ALLO — Allogene Therapeutics Balance Sheet
0.000.00%
- $339.34m
- $66.22m
- $0.02m
- 16
- 41
- 62
- 33
Annual balance sheet for Allogene Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 828 | 457 | 517 | 449 | 292 |
| Net Total Receivables | 2.8 | 1.9 | 1.8 | 1.7 | 1.9 |
| Prepaid Expenses | |||||
| Total Current Assets | 845 | 471 | 529 | 459 | 303 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 160 | 181 | 196 | 163 | 131 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,228 | 1,039 | 822 | 643 | 549 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 94.3 | 48.2 | 53.7 | 37.1 | 35.5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 148 | 122 | 155 | 131 | 127 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1,080 | 916 | 667 | 512 | 422 |
| Total Liabilities & Shareholders' Equity | 1,228 | 1,039 | 822 | 643 | 549 |
| Total Common Shares Outstanding |